Long-Term Dicumarol Administration as a Therapeutic Trial in Sicklemia

Publisher Website
Google Scholar
Abstract
THE management of sicklemia to the present has been restricted to the transfusion of whole blood during the frequent crises of hemolytic anemia. No remedy has been found that will beneficially influence the underlying abnormality — namely, the production of sickle-type (S) hemoglobin in place of adult or normal (A) hemoglobin — or any of the well known secondary manifestations, such as intracapillary thrombosis, which results in cutaneous ulcerations in the pretibial regions, embolism, cranial hyperostosis and arthralgia. The prognosis so far as life is concerned is discouraging, the life expectancy being approximately forty years. In view of the fact . . .

This publication has 0 references indexed in Scilit: